The Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences.
Posted: 7/30/2014 by Prashant Dey in
0
The Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently in Phase III studies. This new licensing agreement will bring relief for as many as 112 countries. These countries tigether make more than 92% of people living with HIV in the developing world. The licence will allow manufacturers in India and China to develop generic versions of TAF.
The Medicines Patent Pool is a United Nations-backed organisation founded in 2010 by UNITAID to increase access to HIV treatment and spur new innovation worldwide. The MPP offers a new public health approach to negotiating patent licences for the production of low-cost versions of new and existing medicines and works with manufacturers to encourage the development of needed new technologies such as FDCs and formulations suitable for children. To date, MPP has signed licensing agreements for eight antiretrovirals and for one medicine for an HIV opportunistic infection. Ten generic manufacturers have now licensed from the organisation.
For complete MPP licensing agreement please click HERE